Acute lymphoblastic leukemia in young adults: Which treatment?

Current Opinion in Oncology

Volumn 24, Issue 5, 2012, Pages 487-494

  McNeer, Jennifer L ^a   Raetz, Elizabeth A ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

acute lymphoblastic leukemia; adolescent and young adult; treatment

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ASPARAGINASE; CORTICOSTEROID; CYTARABINE; TRIACYLGLYCEROL; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT DISEASE; CANCER CENTER; CANCER CHEMOTHERAPY; CANCER CYTODIAGNOSIS; CANCER REGRESSION; CANCER SURVIVAL; CHILDHOOD LEUKEMIA; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG RESPONSE; EVENT FREE SURVIVAL; GENOME; GROUPS BY AGE; HUMAN; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SURVIVAL RATE; SURVIVAL TIME;

ADOLESCENT; ADULT; AGE FACTORS; HUMANS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84865477278     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e32835538f8     Document Type: Review

References (58)

1. Schafer ES, Hunger SP. Optimal therapy for acute lymphoblastic leukemia in adolescents and young adults. Nat Rev Clin Oncol 2011; 8:417-424.
2. Bleyer A. Young adult oncology: the patients and their survival challenges. CA Cancer J Clin 2007; 57:242-255. (Pubitemid 47312083)
3. Pulte D, Gondos A, Brenner H. Improvement in survival in younger patients with acute lymphoblastic leukemia from the 1980 s to the early 21st century. Blood 2009; 113:1408-1411.
4. Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol 2012; 30:1663-1669.
5. 2005. The study included 22 626 individuals with ALL, which is the largest childhood ALL cohort reported to date. Outcomes were analyzed according to age, among other variables.
6. Fern LA, Whelan JS. Recruitment of adolescents and young adults to cancer clinical trials: international comparisons, barriers, and implications. Semin Oncol 2010; 37:e1-e8.
7. Albritton KH, Wiggins CH, Nelson HE, Weeks JC. Site of oncologic specialty care for older adolescents in Utah. J Clin Oncol 2007; 25:4616-4621. (Pubitemid 350035321)
8. Howell DL, Ward KC, Austin HD, et al. Access to pediatric cancer care by age, race, and diagnosis, and outcomes of cancer treatment in pediatric and adolescent patients in the state of Georgia. J Clin Oncol 2007; 25:4610-4615. (Pubitemid 350035320)
9. Yeager ND, Hoshaw-Woodard S, Ruymann FB, Termuhlen A. Patterns of care among adolescents with malignancy in Ohio. J Pediatr Hematol Oncol 2006; 28:17-22. (Pubitemid 43361613)
10. Barry E, DeAngelo DJ, Neuberg D, et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. J Clin Oncol 2007; 25:813-819. (Pubitemid 350002881)
11. Gaynon PS, Trigg ME, Heerema NA, et al. Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995. Leukemia 2000; 14:2223-2233. (Pubitemid 32042263)
12. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004; 104:2690-2696. (Pubitemid 39434949)
13. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Munster. Leukemia 2000; 14:2205-2222. (Pubitemid 32042262)
14. Silverman LB, Declerck L, Gelber RD, et al. Results of Dana-Farber Cancer Institute Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1981-1995). Leukemia 2000; 14:2247-2256. (Pubitemid 32042265)
15. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol 2000; 18:547-561. (Pubitemid 30078536)
16. Boissel N, Auclerc MF, Lheritier V, et al. Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials. J Clin Oncol 2003; 21:774-780. (Pubitemid 46606434)
17. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003; 98:1337-1354. (Pubitemid 37151487)
18. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood 2008; 111:1827-1833. (Pubitemid 351451489)
19. Nachman JB, La MK, Hunger SP, et al. Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. J Clin Oncol 2009; 27:5189-5194.
20. Pui CH, Pei D, Campana D, et al. Improved prognosis for older adolescents with acute lymphoblastic leukemia. J Clin Oncol 2011; 29:386-391.
21. Seibel NL, Steinherz PG, Sather HN, et al. Early postinduction intensification therapy improves survival for children and adolescents with high-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008; 111:2548-2555.
22. DeAngelo DJ, Dahlberg S, Silverman LB, et al. A multicenter phase ii study using a dose intensified pediatric regimen in adults with untreated acute lymphoblastic leukemia. Blood 2007; 110: ASH Meeting Abstracts.
23. de Bont JM, Holt B, Dekker AW, et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands. Leukemia 2004; 18:2032-2035. (Pubitemid 40028431)
24. Hallbook H, Gustafsson G, Smedmyr B, et al. Treatment outcome in young adults and children >10 years of age with acute lymphoblastic leukemia in Sweden: a comparison between a pediatric protocol and an adult protocol. Cancer 2006; 107:1551-1561. (Pubitemid 44546916)
25. Ramanujachar R, Richards S, Hann I, et al. Adolescents with acute lymphoblastic leukaemia: outcome on UK national paediatric (ALL97) and adult (UKALLXII/E2993) trials. Pediatr Blood Cancer 2007; 48:254-261. (Pubitemid 46238513)
26. Stock W, La M, Sanford B, et al. What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood 2008; 112:1646-1654.
27. Usvasalo A, Raty R, Knuutila S, et al. Acute lymphoblastic leukemia in adolescents and young adults in Finland. Haematologica 2008; 93:1161-1168.
28. Ribera JM, Oriol A, Sanz MA, et al. Comparison of the results of the treatment of adolescents and young adults with standard-risk acute lymphoblastic leukemia with the Programa Espanol de Tratamiento en Hematologia pediatric-based protocol ALL-96. J Clin Oncol 2008; 26:1843-1849.
29. Huguet F, Leguay T, Raffoux E, et al. Pediatric-inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL-2003 study. J Clin Oncol 2009; 27:911-918.
30. Stock W. Adolescents and young adults with acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010; 2010:21-29.
31. Harrison CJ. Cytogenetics of paediatric and adolescent acute lymphoblastic leukaemia. Br J Haematol 2009; 144:147-156.
32. Moricke A, Zimmermann M, Reiter A, et al. Prognostic impact of age in children and adolescents with acute lymphoblastic leukemia: data from the trials ALL-BFM 86, 90, and 95. Klin Padiatr 2005; 217:310-320. (Pubitemid 41746112)
33. Harvey RC, Mullighan CG, Chen IM, et al. Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010; 115:5312-5321.
34. Harvey RC, Mullighan CG, Wang X, et al. Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010; 116:4874-4884.
35. Zhang J, Mullighan CG, Harvey RC, et al. Key pathways are frequently mutated in high-risk childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2011; 118:3080-3087.
36. Mullighan CG. New strategies in acute lymphoblastic leukemia: translating advances in genomics into clinical practice. Clin Cancer Res 2011; 17: 396-400.
37. Den Boer ML, van Slegtenhorst M, De Menezes RX, et al. A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study. Lancet Oncol 2009; 10:125-134.
38. Roberts KG, Mullighan CG. How new advances in genetic analysis are influencing the understanding and treatment of childhood acute leukemia. Curr Opin Pediatr 2011; 23:34-40.
39. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360:470-480.
40. Hunger SP, Raetz EA, Loh ML, Mullighan CG. Improving outcomes for highrisk ALL: translating new discoveries into clinical care. Pediatr Blood Cancer 2011; 56:984-993.
41. Mullighan CG, Zhang J, Harvey RC, et al. JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci USA 2009; 106:9414-9418.
42. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446:758-764. (Pubitemid 46582031)
43. Paulsson K, Cazier JB, Macdougall F, et al. Microdeletions are a general feature of adult and adolescent acute lymphoblastic leukemia: unexpected similarities with pediatric disease. Proc Natl Acad Sci USA 2008; 105: 6708-6713. (Pubitemid 351754571)
44. Loh ML, Harvey R, C., Mullighan CG, et al. A BCR-ABL1-like gene expression profile confers a poor prognosis in patients with high-risk acute lymphoblastic leukemia (hr-all): a report from Children's Oncology Group (COG) AALL0232. Blood 2011; 118: ASH Meeting Abstracts.
45. Roberts KG, Morin RD, Zhang J, et al. Novel chromosomal rearrangements and sequence mutations in high-risk ph-like acute lymphoblastic leukemia. Blood 2011; 118: ASH Meeting Abstracts.
46. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. J Clin Oncol 2009; 27: 5175-5181.
47. Borowitz MJ, Devidas M, Hunger SP, et al. Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a children's oncology group study. Blood 2008; 111:5477-5485.
48. Raetz EA, Devidas M, Carroll AJ, et al. Cytogenetic and early-response characteristics of adolescents and young adults with acute lymphoblastic leukemia (ALL): a Children's Oncology Group (COG) study. JCO 2010; 28: ASCO Meeting Abstracts.
49. Freyer DR, Devidas M, La M, et al. Postrelapse survival in childhood acute lymphoblastic leukemia is independent of initial treatment intensity: a report from the Children's Oncology Group. Blood 2011; 117:3010-3015.
50. Veal GJ, Hartford CM, Stewart CF. Clinical pharmacology in the adolescent oncology patient. J Clin Oncol 2010; 28:4790-4799.
51. Yang L, Panetta JC, Cai X, et al. Asparaginase may influence dexamethasone pharmacokinetics in acute lymphoblastic leukemia. J Clin Oncol 2008; 26: 1932-1939.
52. Crom WR, de Graaf SS, Synold T, et al. Pharmacokinetics of vincristine in children and adolescents with acute lymphocytic leukemia. J Pediatr 1994; 125:642-649. (Pubitemid 24318444)
53. Kishi S, Yang W, Boureau B, et al. Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia. Blood 2004; 103:67-72. (Pubitemid 38029919)
54. Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994; 12:1667-1672. (Pubitemid 24245003)
55. Aumente D, Buelga DS, Lukas JC, et al. Population pharmacokinetics of high-dose methotrexate in children with acute lymphoblastic leukaemia. Clin Pharmacokinet 2006; 45:1227-1238. (Pubitemid 44904825)
56. Donelli MG, Zucchetti M, Robatto A, et al. Pharmacokinetics of HD-MTX in infants, children, and adolescents with non-B acute lymphoblastic leukemia. Med Pediatr Oncol 1995; 24:154-159.
57. Stock W, Douer D, DeAngelo DJ, et al. Prevention and management of asparaginase/pegasparaginase-associated toxicities in adults and older adolescents: recommendations of an expert panel. Leuk Lymphoma 2011; 52:2237-2253.
58. Larsen EC, Salzer W, Nachman J, et al. Treatment toxicity in adolescents and young adult (aya) patients compared with younger patients treated for highrisk b-precursor acute lymphoblastic leukemia (HR-ALL): a Report from the Children's Oncology Group Study AALL0232. Blood 2011; 118: ASH Meeting Abstracts.